Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: Transporter specificity and structure-activity relationship

Cancer Chemotherapy and Pharmacology

Volumn 60, Issue 6, 2007, Pages 789-797

  Katayama, Kazuhiro ^a   Masuyama, Kazuto ^a   Yoshioka, Sho ^a   Hasegawa, Hitomi ^a   Mitsuhashi, Junko ^a   Sugimoto, Yoshikazu ^a,b  

^a KEIO UNIVERSITY   (Japan)

^b CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

BCRP ABCG2; Flavonoid; Growth inhibition assay; MRP1 ABCC1; P glycoprotein ABCB1

Indexed keywords

3',4',7 TRIMETHOXYFLAVONE; ABC TRANSPORTER; ACACETIN; BREAST CANCER RESISTANCE PROTEIN; FLAVANOID; GLYCOPROTEIN P; TOPOTECAN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER RESISTANCE; CELL GROWTH; DRUG MECHANISM; DRUG RESISTANCE; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS, HORMONAL; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FLAVONES; FLAVONOIDS; HUMANS; INHIBITORY CONCENTRATION 50; K562 CELLS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP; TOPOTECAN;

EID: 34548580164     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0426-7     Document Type: Article

References (40)

1. Gottesman MM, Hrycyna CA, Schoenlein PV, Germann UA, Pastan I (1995) Genetic analysis of the multidrug transporters. Annu Rev Genet 29:607-649
2. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967-1972
3. Yusa K, Tsuruo T (1989) Reversal mechanism of multidrug resistance by verapamil: direct binding of P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res 49:5002-5006
4. Friedenberg WR, Rue M, Blood EA, Dalton WS, Shustik C, Larson RA, Sonneveld P, Greipp PR (2006) Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer 106:830-838
5. Saeki T, Tsuruo T, Sato W, Nishikawa K (2005) Drug resistance in chemotherapy for breast cancer. Cancer Chemother Pharmacol 56:s84-s89
6. Dieras V, Bonneterre J, Laurence V, Degardin M, Pierga JY, Bonneterre ME, Marreaud S, Lacombe D, Fumoleau P (2005) Phase I combining a P-glycoprotein inhibitor, MS-209, in combination with docetaxel in patients with advanced malignancies. Clin Cancer Res 11:6256-6260
7. Ludwig JP, Szakács G, Martin SE, Chu BF, Cardarelli C, Sauna ZE, Caplen NJ, Fales HM, Ambudkar SV, Weinstein JN, Gottesman MM (2006) Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res 66:4808-4815
8. Tidefelt U, Liliemark J, Gruber A, Liliemark E, Sundman-Engberg B, Juliusson G, Stenke L, Elmhorn-Rosenborg A, Mollgard L, Lehman S, Xu D, Covelli A, Gustavsson B, Paul C (2000) P-glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia. J Clin Oncol 18:1837-1844
9. Nicolantonio FD, Knight LA, Glaysher S, Whitehouse PA, Mercer SJ, Sharma S, Millis L, Prin A, Johnson P, Charlton PA, Norris D, Cree IA (2004) Ex vivo reversal of chemoresistance by tariquidar (XR9576). Anticancer Drugs 15:861-869
10. Robert J, Jarry C (2003) Multidrug resistance reversal agents. J Med Chem 46:4805-4817
11. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T, Bates SE (1999) Molecular cloning of cDNAs which is highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport gene. Cancer Res 59:8-13
12. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665-15670
13. Allikmets R, Schriml L, Hutchinson A, Romano-Spica V, Dean M (1998) A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 58:5337-5339
14. Maliepaard M, van Gastlen MA, de Jong LA, Pluim D, Waardenburg RC, Ruevekamp-Helmers MC (1999) Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 59:4559-4563
15. Kawabata S, Oka M, Shiozawa K, Tsukamoto K, Nakatomi K, Soda H, Fukuda M, Ikegami Y, Sugahara K, Yamada Y, Kamihara S, Doyle LA, Ross DD, Kohno S (2001) Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun 280:1216-1223
16. Kage K, Tsukahara S, Sugiyama T, Asada S, Ishikawa E, Tsuruo T, Sugimoto Y (2002) Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int J Cancer 97:626-630
17. Kage K, Fujita T, Sugimoto Y (2005) Role of Cys-603 in dimer/olligomer formation of the breast cancer resistance protein BCRP/ABCG2. Cancer Sci 96:866-872
18. Fetsch PA, Abati A, Litman T, Morisaki K, Honjo Y, Mittal K, Bates SE, (2006) Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissue. Cancer Lett 23:584-592
19. Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S, Mercer KE, Sarkadi B, Sorrentino BP, Schuetz JD (2004) The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 279:24218-24225
20. Imai Y, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y (2002) Estrone and 17β-estradiol reverse breast cancer resistance protein-mediated multidrug resistance. Jpn J Cancer Res 93:231-235
21. Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y (2003) Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol 64:610-618
22. Imai Y, Tsukahara S, Asada S, Sugimoto Y (2004) Phytoestrogen/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res 64:4346-4352
23. Chen ZS, Aoki S, Komatsu M, Ueda K, Sumizawa T, Furukawa T, Okumura H, Ren XQ, Belinsky MG, Lee K, Kruh GD, Kobayashi M, Akiyama S (2001) Reversal of drug resistance mediated by multidrug resistance protein (MRP) 1 by dual effects of agosterol a on MRP1 function. Int J Cancer 93:107-113
24. Zhang DW, Cole SP, Deeley RG (2001) Identification of an amino acid residue in multidrug resistance protein 1 critical for conferring resistance to anthracyclines. J Biol Chem 276:13231-13239
25. 4 or estradiol-17 (β-D-glucuronate). Biochem Pharmacol 70:1056-1065
26. Sugimoto Y, Tsukahara S, Imai Y, Sugimoto Y, Ueda K, Tsuruo T (2003) Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. Mol Cancer Ther 2:105-112
27. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson JA (1998) Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139:4252-4263
28. Yoshikawa M, Ikegami Y, Sano K, Yoshida H, Mitomi H, Sawada S, Ishikawa T (2004) Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural falavonoid. J Exp Ther Oncol 4:25-35
29. Zhang S, Yang X, Morris ME (2004) Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport. Pharm Res 21:1263-1273
30. Zhang S, Yang X, Morris ME (2004) Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol 65:1208-1216
31. Cooray HC, Janvilisri T, van Veen HW, Hladky SB, Barrand MA (2004) Interaction of the breast cancer resistance protein with plant polyphenols. Biochem Biophys Res Commun 317:269-275
32. Castro AF, Altenberg GA (1997) Inhibition of drug transport by genistein in multidrug-resistance mediated by P-glycoprotein. Biochem Pharmacol 53:89-93
33. Di Pietro A, Conseil G, Perez-Victoria JM, Dayan G, Baubichon-Cortay H, Trompier D, Steinfels E, Jault JM, de Wet H, Maitrejean M, Comte G, Boumendjel A, Mariotte AM, Dumontet C, Mclntosh DB, Goffeau A, Castanys S, Gamarro F, Barron D (2002) Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. Cell Mol Life Sci 59:307-322
34. Zhang S, Morris ME (2003) Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 304:1258-1267
35. Walgren RA, Karnaky KJ Jr., Lindenmayer GE, Walle T (2000) Efflux of dietary flavonoid quercetin 4′-β-glucoside across human intestinal Caco-2 cell monolayers by apical multidrug resistance-associated protein-2. J Pharmacol Exp Ther 294:830-836
36. Versantvoort CH, Broxterman HJ, Lankelma J, Feller N, Pinedo HM (1994) Competitive inhibiton by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells. Biochem Pharmacol 48:1129-1136
37. Singh AK, Schultz BD, Katzenellenbogen JA, Price EM, Bridges RJ, Bradbury NA (2000) Estrogen inhibition of cystic fibrosis transmembrane conductance regulator-mediated chloride secretion. J Pharmacol Exp Ther 295:195-204
38. Robey RW, Medina-Perez WY, Nishiyama K, Lahusen T, Miyake K, Litman T, Senderowicz AM, Ross DD, Bates SE (2001) Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 7:145-152
39. Hollman PC, Katan MB (1999) Dietary flavonoids: intake, health effects and bioavailability. Food Chem Toxicol 37:937-942
40. Setchell KD, Brown NM, Desai P, Zimmer-Nechemias L, Wolfe BE, Brashear WT, Kirschner AS, Cassidy A, Heubi JE (2001) Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr 131:1362S-1375S